IGM Biosciences Inc. (IGMS) Reports Q4 Loss of $0.79/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
IGM Biosciences Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
March 30, 2021 4:17 PM EDTRecommended Phase 2 Dose for IGM-2323 Expected in 2021
Initial Data from Phase 1 Trial of IGM-8444 in Solid Cancers Expected in 2021
IND Filing for IGM-7354 Planned in 2021
Company to Host Conference Call Today at 4:30 p.m. ET
MOUNTAIN VIEW, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the fourth quarter and full year ended December 31, 2020 and provided an update on recent... More
